Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

被引：100

作者：

Rodrigues, Manuel ^{[1
,2
]}

Mobuchon, Lenha ^{[1
]}

Houy, Alexandre ^{[1
]}

Fievet, Alice ^{[1
,3
]}

Gardrat, Sophie ^{[4
]}

Barnhill, Raymond L. ^{[4
,5
]}

Popova, Tatiana ^{[1
]}

Servois, Vincent ^{[6
]}

Rampanou, Aurore ^{[7
]}

Mouton, Aurore ^{[8
]}

Dayot, Stephane ^{[1
]}

Raynal, Virginie ^{[9
,10
]}

Galut, Michele ^{[11
]}

Putterman, Marc ^{[12
]}

Tick, Sarah ^{[13
]}

Cassoux, Nathalie ^{[5
,14
]}

Roman-Roman, Sergio ^{[15
]}

Bidard, Francois-Clement ^{[2
,7
,16
]}

Lantz, Olivier ^{[8
]}

Mariani, Pascale ^{[17
]}

Piperno-Neumann, Sophie ^{[2
]}

Stern, Marc-Henri ^{[1
,3
]}

机构：

[1] PSL Res Univ, Inst Curie, INSERM U830, DRUM,Equipe Labellisee Ligue Natl Canc, F-75248 Paris, France

[2] PSL Res Univ, Inst Curie, Dept Med Oncol, F-75248 Paris, France

[3] PSL Res Univ, Inst Curie, Dept Genet, F-75248 Paris, France

[4] PSL Res Univ, Inst Curie, Dept Biopathol, F-75248 Paris, France

[5] Univ Paris 05, Fac Med, F-75006 Paris, France

[6] PSL Res Univ, Inst Curie, Dept Med Imaging, F-75248 Paris, France

[7] PSL Res Univ, Inst Curie, Lab Circulating Tumor Biomarkers, SiRIC, F-75248 Paris, France

[8] PSL Res Univ, Inst Curie, INSERM CIC BT 1428, F-75248 Paris, France

[9] PSL Res Univ, Inst Curie, INSERM U830, F-75248 Paris, France

[10] Inst Curie Genom Excellence ICGex Platform, F-75248 Paris, France

[11] PSL Res Univ, Inst Curie, Biol Resource Ctr, F-75248 Paris, France

[12] Quinze Vingts Natl Ophthalmol Hosp, Dept Pathol, F-75012 Paris, France

[13] Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol 3, F-75012 Paris, France

[14] PSL Res Univ, Inst Curie, Dept Ocular Oncol, F-75248 Paris, France

[15] PSL Res Univ, Inst Curie, Dept Translat Res, F-75248 Paris, France

[16] Paris Saclay Univ, UVSQ, F-78035 St Quentin en Yvelines, France

[17] PSL Res Univ, Inst Curie, Dept Surg Oncol, F-75248 Paris, France

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

CANCER; DNA; IDENTIFICATION; BLOCKADE; DATABASE; CELLS; PD-1;

D O I：

10.1038/s41467-018-04322-5

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Metastatic uveal melanoma is a deadly disease with no proven standard of care. Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor. We identify additional tumors in The Cancer Genome Atlas (TCGA) cohorts with similar hypermutator profiles in patients carrying germline deleterious MBD4 mutations and somatic loss of heterozygosity. This MBD4-related hypermutator phenotype may explain unexpected responses to immune checkpoint inhibitors.

引用

页数：6

共 50 条

[31] Somatic frameshift mutations in MBD4 (MED1) are not exclusively associated with microsatellite high (MSI-H) colorectal tumors
Goel, A
Arnold, CN
Ricciardiello, L
Chang, DK
Wasserman, L
Compton, C
Niedzwiecki, D
Mayer, RJ
Bertagnolli, MM
Boland, R
GASTROENTEROLOGY, 2001, 120 (05) : A293 - A293
[32] AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers
Gschwind, Axel
Ossowski, Stephan
CANCERS, 2025, 17 (05)
[33] Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
Cuevas, Eleonora Sosa
Mouret, Stephane
Vayssiere, Guillaume
Kerboua, Siham
Girard, Pauline
Molens, Jean-Paul
Manceau, Marc
Charles, Julie
Saas, Philippe
Aspord, Caroline
FRONTIERS IN IMMUNOLOGY, 2024, 15
[34] Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.
Bayan, Claire-Audrey
Gartrell, Robyn Denise
Komatsubara, Kimberly Mayumi
Pradhan, Jaya Sarin
Marks, Douglas Kanter
Lu, Yan
Borgardus, Margaret
Hasan, Syed Shabee
Lopez, Adriana
Hart, Thomas D.
Geskin, Larisa J.
Taback, Bret
Carvajal, Richard D.
Schwartz, Gary K.
Horst, Basil
Saenger, Yvonne M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[35] Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma
Indini, Alice
Di Guardo, Lorenza
Cimminiello, Carolina
De Braud, Filippo
Del Vecchio, Michele
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (08): : 643 - 648
[36] Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis
Johnson, Douglas B.
Bao, Riyue
Ancell, Kristin K.
Daniels, Anthony B.
Wallace, Deborah
Sosman, Jeffrey A.
Luke, Jason J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02): : 114 - 117
[37] Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma
Rose, A. A. N.
Kelly, D.
Hogg, D.
Butler, M. O.
Saibil, S.
Krema, H.
King, I.
Kamil, Z. Saeed
Ghazarian, D.
Ceballos, D. P. Arteaga
Araujo, D. V.
Muniz, T.
Waldron, J.
Laperriere, N.
Spreafico, A.
ANNALS OF ONCOLOGY, 2020, 31 : S764 - S765
[38] Mechanisms of response to anti-PD1 (PD1) combined with Ipilimumab (IPI) in patients (pts) with PD1-resistant metastatic melanoma (MM)
da Silva, Ines Pires
Conway, Jordan
Edwards, Jarem
Marsh-Wakefield, Felix
Quek, Camelia
Ferguson, Angela
Johnansson, Peter
Carlino, Matteo
Menzies, Alexander
Wilmott, James
Palendira, Umaimainthan
Scolyer, Richard
Long, Georgina
CANCER RESEARCH, 2024, 84 (06)
[39] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, Muhammad Zubair
Mabaera, Rodwell
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[40] Proteomic and Metabolomic Profiling of Female Patients with advanced Melanoma to Predict and Monitor Response to anti-PD1 Immunotherapy
Paulitschke, V.
Zila, N.
Bileck, A.
Stary, G.
Borik-Heil, L.
Dadak, L.
Wolf, M.
Wasinger, D.
Aguilar-Gonzales, A.
Harikumar, N.
Kunstfeld, R.
Weninger, W. P.
Hoeller, C.
Gerner, C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024, 22 : 33 - 34

← 1 2 3 4 5 →